Latest Proteasome Stories
EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.
EMERYVILLE, Calif., May 20 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
BOSTON and SAN DIEGO, March 3 /PRNewswire/ -- Stemgent, Inc., a biotechnology company based in San Diego, California, and Boston, Massachusetts, USA, announced today the formation of Ubiquigent Ltd, a new biotechnology company based in Dundee, Scotland.
Proteosome inhibitors can rescue mutant proteins without altering the DNA of mutant genes.
Carfilzomib induces a response in 45 percent of patients and reduces neuropathy.
EMERYVILLE, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens.
SOUTH SAN FRANCISCO, Oct. 17 /PRNewswire/ -- Proteolix, Inc. today announced that data from preclinical studies of carfilzomib and PR-957 will be presented at the 2009 ACR/ARHP Annual Scientific Meeting on October 16 - 21 in Philadelphia, PA.
SOUTH SAN FRANCISCO, Calif., Oct. 12 /PRNewswire/ -- Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX).
EMERYVILLE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
- Growing in low tufty patches.